Reindl Lisa Marie, Albinger Nawid, Bexte Tobias, Müller Stephan, Hartmann Jessica, Ullrich Evelyn
Children's Hospital, Goethe-University Frankfurt, Frankfurt am Main, Germany.
Experimental Immunology, Goethe University Frankfurt, Frankfurt am Main, Germany.
Oncoimmunology. 2020 Sep 2;9(1):1777651. doi: 10.1080/2162402X.2020.1777651.
Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual killing-capacity by CAR-dependent and -independent mechanisms and induce few side effects. While the majority of trials still use CAR-T cells, CAR-NK cell trials are on the rise with 19 ongoing studies worldwide. This review illuminates the current state of research and clinical application of CAR-NK cells, as well as future developmental potential.
嵌合抗原受体（CAR）-T细胞疗法已取得显著成功。然而，诸如细胞因子释放综合征或神经毒性等与应用相关的毒性，使自然杀伤（NK）细胞成为免疫疗法中的新焦点。CAR-NK细胞通过CAR依赖和非依赖机制提供有利的双重杀伤能力，且副作用较少。虽然大多数试验仍使用CAR-T细胞，但CAR-NK细胞试验正在增加，全球有19项正在进行的研究。本综述阐明了CAR-NK细胞的研究现状、临床应用以及未来的发展潜力。
Zotero 插件